C. R. Bard, Inc., together with its subsidiaries, is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. Products The company offers its products in four major product group categories: vascular, urology, oncology and surgical specialties. The company also has a product group of other products. Vascular Products The company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The company’s vena cava filters product line includes devices which can be either permanently implanted or retrieved after the threat of blood clots traveling from the lower extremities to a patient’s lungs has passed. It offers a portfolio of automatic core needle biopsy devices, including MaxCore and Magnum. It offers EnCor and EnCor Enspire breast biopsy systems for ultrasound-, stereotactic- and MRI-guided breast biopsy procedures. With SenoRx products, the company offers a variety of products across the percutaneous breast biopsy and tissue marker segments. Urology Products The company’s urology products include basic drainage products, continence products and urological specialty products. Its Foley catheters include the infection control Foley catheter (Bardex I.C. Foley catheter), which reduce the rate of urinary tract infections. Other urology products include surgical slings used to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; and specialty devices for stone removal procedures. The company also markets the proprietary line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters, thereby reducing restarts and other complications. These devices are also used to secure many other types of catheters sold by the company and other companies, including Foley catheters. In 2011, the company acquired Medivance, Inc. whose Arctic Sun system with proprietary ArcticGel pads provides Targeted Temperature Management therapy to patients requiring therapeutic hypothermia. Oncology Products The company’s oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices. The company’s PowerPICC catheters and PowerPort devices can also be used to inject contrast media at high flow rates. These devices eliminate the need to place an additional catheter in the significant number of PICC and port recipients who also require contrast enhanced CT (computed tomography) scans. The company’s Site-Rite vascular access ultrasound device and Sherlock tip locator system help nurses place a PICC at a patient’s bedside, making PICCs a treatment option. Surgical Specialty Products The company’s surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The company’s soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The company has a full line of products for inguinal (groin) hernias including the Perfix Plug and 3D Max product lines. It also has the Phasix line of products, which includes advanced polymer technology based on a fully absorbable platform that is absorbed naturally by the body over time. The company also markets products for the repair of ventral (abdominal) hernias including the Ventrio, Ventrio ST, Ventralex, Ventralex ST and Ventralight ST synthetic grafts. In October 2013, the company acquired Medafor, Inc. and its Arista AH plant-based hemostat product line complementing its Progel surgical sealant technology. International Through subsidiaries and a joint venture, the company markets its products to customers in approximately 100 countries outside the United States. The company’s principal international markets are in Europe and Japan. Sales and Marketing The company’s products are distributed domestically directly to hospitals and other healthcare institutions, as well as through hospital/surgical supply and other medical specialty distributors with whom the company has distribution agreements. Trademarks Most of the products sold by the company, whether manufactured by the company or by others, are sold under the BARD trade name. Research and Development The company’s research and development expenditures, including acquired in-process research and development, were $295.7 million in 2013. History C. R. Bard, Inc. was founded in 1907. The company was incorporated in 1923.
cr bard inc (BCR:New York)
730 Central Avenue
Murray Hill, NJ 07974
|CareFusion Corp||$59.56 USD||-0.18|
|Edwards Lifesciences Corp||$128.87 USD||-0.51|
|Endo International PLC||$81.19 USD||+1.47|
|Hospira Inc||$64.65 USD||-0.84|
|Varian Medical Systems Inc||$86.52 USD||-0.55|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.